Subscribe To
CELZ / Creative Medical (CELZ) Up 82% on Stem Cell Treatment Data
CELZ News
By Zacks Investment Research
September 22, 2023
What Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy Stock
Creative Medical Technology Holdings, Inc. (CELZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings more_horizontal
By Zacks Investment Research
April 13, 2023
Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data
Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes more_horizontal
By InvestorPlace
February 8, 2023
Why Is Creative Medical (CELZ) Stock Up 121% Today?
Creative Medical (NASDAQ: CELZ ) stock is rocketing higher on Wednesday thanks to clearance for a new clinical trial. That clearance comes from the FD more_horizontal
By PennyStocks
March 25, 2022
Top Must-Watch Penny Stocks For Your April List
Are these penny stocks on your April watchlist? The post Top Must-Watch Penny Stocks For Your April List appeared first on Penny Stocks to Buy, Pick more_horizontal
By Zacks Investment Research
March 24, 2022
Creative Medical (CELZ) Up 82% on Stem Cell Treatment Data
Creative Medical Technology (CELZ) reports positive follow-up data from a pilot study evaluating StemSpine, a patented stem cell treatment for chronic more_horizontal
By InvestorPlace
March 23, 2022
Why Is Creative Medical Technology (CELZ) Stock Up Today?
Creative Medical Technology announced positive results concerning its StemSpine procedure. Here's what you should know as CELZ stock rises. more_horizontal
By Benzinga
March 23, 2022
Why Creative Medical Technology Shares Are Soaring
Creative Medical Technology Holdings Inc (NASDAQ: CELZ) shares are trading higher Wednesday after the company announced top-line results for its follo more_horizontal
By Benzinga
March 23, 2022
Creative Medical Shares Soar On Positive Data from StemSpine Pilot Study
Creative Medical Technology Holdings (NASDAQ: CELZ) has announced positive two-year follow-up data from its StemSpine pilot study. more_horizontal